396 related articles for article (PubMed ID: 25926246)
21. Real-world effectiveness and safety of omalizumab in patients with uncontrolled severe allergic asthma from the Czech Republic.
Kirchnerová OR; Valena T; Novosad J; Teřl M;
Postepy Dermatol Alergol; 2019 Feb; 36(1):34-43. PubMed ID: 30858777
[TBL] [Abstract][Full Text] [Related]
22. [Analysis of asthma control and quality of life in severe allergic asthmatics under treatment with anti-IgE, omalizumab].
Pacheco-Galván A; Hinojosa-Macías M; Hurtado-Barbudo B; González-Cervera J; Sueiro-Bendito A
Med Clin (Barc); 2009 Oct; 133(12):460-3. PubMed ID: 19775710
[TBL] [Abstract][Full Text] [Related]
23. Omalizumab therapy in severe asthma: experience from the Spanish registry--some new approaches.
Vennera Mdel C; Pérez De Llano L; Bardagí S; Ausin P; Sanjuas C; González H; Gullón JA; Martínez-Moragón E; Carretero JA; Vera E; Medina JF; Alvarez FJ; Entrenas LM; Padilla A; Irigaray R; Picado C;
J Asthma; 2012 May; 49(4):416-22. PubMed ID: 22443408
[TBL] [Abstract][Full Text] [Related]
24. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.
Tzortzaki EG; Georgiou A; Kampas D; Lemessios M; Markatos M; Adamidi T; Samara K; Skoula G; Damianaki A; Schiza S; Tzanakis N; Siafakas NM
Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001
[TBL] [Abstract][Full Text] [Related]
25. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety.
Mansur AH; Srivastava S; Mitchell V; Sullivan J; Kasujee I
Respir Med; 2017 Mar; 124():36-43. PubMed ID: 28284319
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry.
Gibson PG; Reddel H; McDonald VM; Marks G; Jenkins C; Gillman A; Upham J; Sutherland M; Rimmer J; Thien F; Katsoulotos GP; Cook M; Yang I; Katelaris C; Bowler S; Langton D; Robinson P; Wright C; Yozghatlian V; Burgess S; Sivakumaran P; Jaffe A; Bowden J; Wark PA; Yan KY; Kritikos V; Peters M; Hew M; Aminazad A; Bint M; Guo M
Intern Med J; 2016 Sep; 46(9):1054-62. PubMed ID: 27350385
[TBL] [Abstract][Full Text] [Related]
27. Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: A long-term post-marketing study in Japan.
Adachi M; Kozawa M; Yoshisue H; Lee Milligan K; Nagasaki M; Sasajima T; Miyamoto T; Ohta K
Respir Med; 2018 Aug; 141():56-63. PubMed ID: 30053973
[TBL] [Abstract][Full Text] [Related]
28. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma.
Bardelas J; Figliomeni M; Kianifard F; Meng X
J Asthma; 2012 Mar; 49(2):144-52. PubMed ID: 22277052
[TBL] [Abstract][Full Text] [Related]
29. Real-life long-term safety and effectiveness of omalizumab in Japanese pediatric patients with severe allergic asthma: A post-marketing surveillance.
Nakamura N; Kashitani Y; Yoshisue H; Nagasaki M; Sasajima T
Allergol Int; 2021 Jul; 70(3):319-326. PubMed ID: 33526351
[TBL] [Abstract][Full Text] [Related]
30. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma.
Ohta K; Miyamoto T; Amagasaki T; Yamamoto M;
Respirology; 2009 Nov; 14(8):1156-65. PubMed ID: 19909462
[TBL] [Abstract][Full Text] [Related]
32. Development of the Asthma Control Composite outcome measure to predict omalizumab response.
Harris JM; Wong DA; Kapp AV
Ann Allergy Asthma Immunol; 2011 Sep; 107(3):273-80.e1. PubMed ID: 21875548
[TBL] [Abstract][Full Text] [Related]
33. The real-life clinical effects of 52 weeks of omalizumab therapy for severe persistent allergic asthma.
Gouder C; West LM; Montefort S
Int J Clin Pharm; 2015 Feb; 37(1):36-43. PubMed ID: 25394832
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
Holgate ST; Chuchalin AG; Hébert J; Lötvall J; Persson GB; Chung KF; Bousquet J; Kerstjens HA; Fox H; Thirlwell J; Cioppa GD;
Clin Exp Allergy; 2004 Apr; 34(4):632-8. PubMed ID: 15080818
[TBL] [Abstract][Full Text] [Related]
35. The "real-world" effectiveness and safety of omalizumab in patients with uncontrolled persistent allergic asthma in Slovakia: a subgroup analysis of the eXpeRience study.
Siracká S; Tinková LD; Hochmuth L; Leščišinová H; Hrubiško M; Dostálová K; Jeseňák M
Postepy Dermatol Alergol; 2023 Feb; 40(1):134-141. PubMed ID: 36909923
[TBL] [Abstract][Full Text] [Related]
36. [Omalizumab in children with uncontrolled asthma: a real-life study carried out in Colombia].
Morales-Múnera O; Pedraza Á; Niño-Serna L
Rev Alerg Mex; 2018; 65(3):222-232. PubMed ID: 30176200
[TBL] [Abstract][Full Text] [Related]
37. Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study).
Niven RM; Saralaya D; Chaudhuri R; Masoli M; Clifton I; Mansur AH; Hacking V; McLain-Smith S; Menzies-Gow A
BMJ Open; 2016 Aug; 6(8):e011857. PubMed ID: 27507234
[TBL] [Abstract][Full Text] [Related]
38. Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study.
Casale TB; Luskin AT; Busse W; Zeiger RS; Trzaskoma B; Yang M; Griffin NM; Chipps BE
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):156-164.e1. PubMed ID: 29800752
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience.
Kupryś-Lipińska I; Majak P; Molinska J; Kuna P
BMC Pulm Med; 2016 Apr; 16(1):61. PubMed ID: 27117315
[TBL] [Abstract][Full Text] [Related]
40. Long-term evaluation of response to omalizumab therapy in real life by a novel multimodular approach: The Real-life Effectiveness of Omalizumab Therapy (REALITY) study.
Singh H; Peters JI; Kaur Y; Maselli DJ; Diaz JD
Ann Allergy Asthma Immunol; 2019 Nov; 123(5):476-482.e1. PubMed ID: 31382020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]